125 related articles for article (PubMed ID: 38429995)
21. Polygenic Risk Score Modifies Prostate Cancer Risk of Pathogenic Variants in Men of African Ancestry.
Hughley RW; Matejcic M; Song Z; Sheng X; Wan P; Xia L; Hart SN; Hu C; Yadav S; Lubmawa A; Kiddu V; Asiimwe F; Amanya C; Mutema G; Job K; Ssebakumba MK; Ingles SA; Hamilton AS; Couch FJ; Watya S; Conti DV; Darst BF; Haiman CA
Cancer Res Commun; 2023 Dec; 3(12):2544-2550. PubMed ID: 38014910
[TBL] [Abstract][Full Text] [Related]
22. Protocol for the PRIMARY clinical trial, a prospective, multicentre, cross-sectional study of the additive diagnostic value of gallium-68 prostate-specific membrane antigen positron-emission tomography/computed tomography to multiparametric magnetic resonance imaging in the diagnostic setting for men being investigated for prostate cancer.
Amin A; Blazevski A; Thompson J; Scheltema MJ; Hofman MS; Murphy D; Lawrentschuk N; Sathianathen N; Kapoor J; Woo HH; Chalasani V; Rasiah K; van Leeuwen PJ; Tang R; Cusick T; Stricker P; Emmett L
BJU Int; 2020 Apr; 125(4):515-524. PubMed ID: 31957122
[TBL] [Abstract][Full Text] [Related]
23. Accurate diagnosis of prostate cancer by combining Proclarix with magnetic resonance imaging.
Morote J; Pye H; Campistol M; Celma A; Regis L; Semidey M; de Torres I; Mast R; Planas J; Santamaria A; Trilla E; Athanasiou A; Singh S; Heavey S; Stopka-Farooqui U; Freeman A; Haider A; Schiess R; Whitaker HC; Punwani S; Ahmed HU; Emberton M
BJU Int; 2023 Aug; 132(2):188-195. PubMed ID: 36855895
[TBL] [Abstract][Full Text] [Related]
24. Clinical Utility of Germline Genetic Testing in Japanese Men Undergoing Prostate Biopsy.
Akamatsu S; Terada N; Takata R; Kinoshita H; Shimatani K; Momozawa Y; Yamamoto M; Tada H; Kawamorita N; Narita S; Kato T; Nitta M; Kandori S; Koike Y; Inazawa J; Kimura T; Kimura H; Kojima T; Terachi T; Sugimoto M; Habuchi T; Arai Y; Yamamoto S; Matsuda T; Obara W; Kamoto T; Inoue T; Nakagawa H; Ogawa O
JNCI Cancer Spectr; 2022 Feb; 6(1):. PubMed ID: 35118230
[TBL] [Abstract][Full Text] [Related]
25. Diagnostic Accuracy of Single-plane Biparametric and Multiparametric Magnetic Resonance Imaging in Prostate Cancer: A Randomized Noninferiority Trial in Biopsy-naïve Men.
Russo F; Mazzetti S; Regge D; Ambrosini I; Giannini V; Manfredi M; De Luca S; Bollito E; Porpiglia F
Eur Urol Oncol; 2021 Dec; 4(6):855-862. PubMed ID: 33893066
[TBL] [Abstract][Full Text] [Related]
26. What Type of Prostate Cancer Is Systematically Overlooked by Multiparametric Magnetic Resonance Imaging? An Analysis from the PROMIS Cohort.
Norris JM; Carmona Echeverria LM; Bott SRJ; Brown LC; Burns-Cox N; Dudderidge T; El-Shater Bosaily A; Frangou E; Freeman A; Ghei M; Henderson A; Hindley RG; Kaplan RS; Kirkham A; Oldroyd R; Parker C; Persad R; Punwani S; Rosario DJ; Shergill IS; Stavrinides V; Winkler M; Whitaker HC; Ahmed HU; Emberton M
Eur Urol; 2020 Aug; 78(2):163-170. PubMed ID: 32370911
[TBL] [Abstract][Full Text] [Related]
27. Multiparametric magnetic resonance imaging predicts the presence of prostate cancer in patients with negative prostate biopsy.
Lista F; Castillo E; Gimbernat H; Rodríguez-Barbero JM; Panizo J; Angulo JC
Actas Urol Esp; 2015 Mar; 39(2):85-91. PubMed ID: 25267460
[TBL] [Abstract][Full Text] [Related]
28. Elucidating the need for prostate cancer risk calculators in conjunction with mpMRI in initial risk assessment before prostate biopsy at a tertiary prostate cancer center.
Krausewitz P; Büttner T; von Danwitz M; Weiten R; Cox A; Klümper N; Stein J; Luetkens J; Kristiansen G; Ritter M; Ellinger J
BMC Urol; 2024 Mar; 24(1):71. PubMed ID: 38532370
[TBL] [Abstract][Full Text] [Related]
29. What Is the Negative Predictive Value of Multiparametric Magnetic Resonance Imaging in Excluding Prostate Cancer at Biopsy? A Systematic Review and Meta-analysis from the European Association of Urology Prostate Cancer Guidelines Panel.
Moldovan PC; Van den Broeck T; Sylvester R; Marconi L; Bellmunt J; van den Bergh RCN; Bolla M; Briers E; Cumberbatch MG; Fossati N; Gross T; Henry AM; Joniau S; van der Kwast TH; Matveev VB; van der Poel HG; De Santis M; Schoots IG; Wiegel T; Yuan CY; Cornford P; Mottet N; Lam TB; Rouvière O
Eur Urol; 2017 Aug; 72(2):250-266. PubMed ID: 28336078
[TBL] [Abstract][Full Text] [Related]
30. Risk-based Patient Selection for Magnetic Resonance Imaging-targeted Prostate Biopsy after Negative Transrectal Ultrasound-guided Random Biopsy Avoids Unnecessary Magnetic Resonance Imaging Scans.
Alberts AR; Schoots IG; Bokhorst LP; van Leenders GJ; Bangma CH; Roobol MJ
Eur Urol; 2016 Jun; 69(6):1129-34. PubMed ID: 26651990
[TBL] [Abstract][Full Text] [Related]
31. The role of prostate-specific antigen density and negative multiparametric magnetic resonance imaging in excluding prostate cancer for biopsy-naïve men: clinical outcomes from a high-volume center in China.
Zhang CC; Tu X; Lin TH; Cai DM; Yang L; Nie L; Qiu S; Liu ZH; Jin K; Li JK; Xiong XY; Yang L; Wei Q
Asian J Androl; 2022; 24(6):615-619. PubMed ID: 35532555
[TBL] [Abstract][Full Text] [Related]
32. How to optimize follow-up in patients with a suspicious multiparametric MRI and a subsequent negative targeted prostate biopsy. Results from a large, single-institution series.
Barletta F; Stabile A; Mazzone E; Brembilla G; Sorce G; Pellegrino F; Scuderi S; Cannoletta D; Cirulli GO; Cucchiara V; Gandaglia G; De Cobelli F; Montorsi F; Briganti A
Urol Oncol; 2022 Mar; 40(3):103.e17-103.e24. PubMed ID: 34688534
[TBL] [Abstract][Full Text] [Related]
33. Genomic Evaluation of Multiparametric Magnetic Resonance Imaging-visible and -nonvisible Lesions in Clinically Localised Prostate Cancer.
Parry MA; Srivastava S; Ali A; Cannistraci A; Antonello J; Barros-Silva JD; Ubertini V; Ramani V; Lau M; Shanks J; Nonaka D; Oliveira P; Hambrock T; Leong HS; Dhomen N; Miller C; Brady G; Dive C; Clarke NW; Marais R; Baena E
Eur Urol Oncol; 2019 Feb; 2(1):1-11. PubMed ID: 30929837
[TBL] [Abstract][Full Text] [Related]
34. Negative Biopsy Histology in Men With PI-RADS Score 5 in Daily Clinical Practice: Incidence of Granulomatous Prostatitis.
Pepe P; Pennisi M
Clin Genitourin Cancer; 2020 Dec; 18(6):e684-e687. PubMed ID: 32389459
[TBL] [Abstract][Full Text] [Related]
35. Targeted multiparametric magnetic resonance imaging/transrectal ultrasound-guided (mpMRI/TRUS) fusion prostate biopsy versus systematic random prostate biopsy: A comparative real-life study.
Pham THN; Schulze-Hagen MF; Rahnama'i MS
Cancer Rep (Hoboken); 2024 Feb; 7(2):e1962. PubMed ID: 38217298
[TBL] [Abstract][Full Text] [Related]
36. The influence of prostate-specific antigen density on positive and negative predictive values of multiparametric magnetic resonance imaging to detect Gleason score 7-10 prostate cancer in a repeat biopsy setting.
Hansen NL; Barrett T; Koo B; Doble A; Gnanapragasam V; Warren A; Kastner C; Bratt O
BJU Int; 2017 May; 119(5):724-730. PubMed ID: 27488931
[TBL] [Abstract][Full Text] [Related]
37. Evidence of Novel Susceptibility Variants for Prostate Cancer and a Multiancestry Polygenic Risk Score Associated with Aggressive Disease in Men of African Ancestry.
Chen F; Madduri RK; Rodriguez AA; Darst BF; Chou A; Sheng X; Wang A; Shen J; Saunders EJ; Rhie SK; Bensen JT; Ingles SA; Kittles RA; Strom SS; Rybicki BA; Nemesure B; Isaacs WB; Stanford JL; Zheng W; Sanderson M; John EM; Park JY; Xu J; Wang Y; Berndt SI; Huff CD; Yeboah ED; Tettey Y; Lachance J; Tang W; Rentsch CT; Cho K; Mcmahon BH; Biritwum RB; Adjei AA; Tay E; Truelove A; Niwa S; Sellers TA; Yamoah K; Murphy AB; Crawford DC; Patel AV; Bush WS; Aldrich MC; Cussenot O; Petrovics G; Cullen J; Neslund-Dudas CM; Stern MC; Kote-Jarai Z; Govindasami K; Cook MB; Chokkalingam AP; Hsing AW; Goodman PJ; Hoffmann TJ; Drake BF; Hu JJ; Keaton JM; Hellwege JN; Clark PE; Jalloh M; Gueye SM; Niang L; Ogunbiyi O; Idowu MO; Popoola O; Adebiyi AO; Aisuodionoe-Shadrach OI; Ajibola HO; Jamda MA; Oluwole OP; Nwegbu M; Adusei B; Mante S; Darkwa-Abrahams A; Mensah JE; Diop H; Van Den Eeden SK; Blanchet P; Fowke JH; Casey G; Hennis AJ; Lubwama A; Thompson IM; Leach R; Easton DF; Preuss MH; Loos RJ; Gundell SM; Wan P; Mohler JL; Fontham ET; Smith GJ; Taylor JA; Srivastava S; Eeles RA; Carpten JD; Kibel AS; Multigner L; Parent MÉ; Menegaux F; Cancel-Tassin G; Klein EA; Andrews C; Rebbeck TR; Brureau L; Ambs S; Edwards TL; Watya S; Chanock SJ; Witte JS; Blot WJ; Michael Gaziano J; Justice AC; Conti DV; Haiman CA
Eur Urol; 2023 Jul; 84(1):13-21. PubMed ID: 36872133
[TBL] [Abstract][Full Text] [Related]
38. The significance of anterior prostate lesions on multiparametric magnetic resonance imaging in African-American men.
Kongnyuy M; Sidana A; George AK; Muthigi A; Iyer A; Fascelli M; Kadakia M; Frye TP; Ho R; Mertan F; Minhaj Siddiqui M; Su D; Merino MJ; Turkbey B; Choyke PL; Wood BJ; Pinto PA
Urol Oncol; 2016 Jun; 34(6):254.e15-21. PubMed ID: 26905304
[TBL] [Abstract][Full Text] [Related]
39. Association between a 17-gene genomic prostate score and multi-parametric prostate MRI in men with low and intermediate risk prostate cancer (PCa).
Leapman MS; Westphalen AC; Ameli N; Lawrence HJ; Febbo PG; Cooperberg MR; Carroll PR
PLoS One; 2017; 12(10):e0185535. PubMed ID: 29016610
[TBL] [Abstract][Full Text] [Related]
40. The "Is mpMRI Enough" or IMRIE Study: A Multicentre Evaluation of Prebiopsy Multiparametric Magnetic Resonance Imaging Compared with Biopsy.
Stonier T; Simson N; Shah T; Lobo N; Amer T; Lee SM; Bass E; Chau E; Grey A; McCartan N; Acher P; Ahmad I; Arumainayagam N; Brown D; Chapman A; Elf D; Hartington T; Ibrahim I; Leung H; Liyanage S; Lovegrove C; Malthouse T; Mateen B; Mistry K; Morrison I; Nalagatla S; Persad R; Pope A; Sokhi H; Syed H; Tadtayev S; Tharmaratnam M; Qteishat A; Miah S; Emberton M; Moore C; Walton T; Eddy B; Ahmed HU
Eur Urol Focus; 2021 Sep; 7(5):1027-1034. PubMed ID: 33046412
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
